UBS Group’s ImageneBio IMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$32.8K Buy
7,163
+284
+4% +$1.54K ﹤0.01% 8018
2026
Q2
$40.6K Buy
6,879
+1,451
+27% +$8.19K ﹤0.01% 7688
2026
Q1
$27.1K Buy
5,428
+467
+9% +$3.03K ﹤0.01% 7755
2025
Q4
$34.2K Buy
4,961
+191
+4% +$1.42K ﹤0.01% 7447
2025
Q3
$38.9K Sell
4,770
-1,452
-23% -$19.2K ﹤0.01% 7737
2025
Q2
$100K Sell
6,222
-2,166
-26% -$31.8K ﹤0.01% 7239
2025
Q1
$129K Buy
8,388
+2,400
+40% +$41.4K ﹤0.01% 6847
2024
Q4
$118K Buy
5,988
+5,982
+99,700% +$121K ﹤0.01% 6772
2024
Q3
$125 Sell
6
-3,479
-100% -$70.4K ﹤0.01% 9134
2024
Q2
$69K Buy
3,485
+756
+28% +$13.3K ﹤0.01% 6439
2024
Q1
$46.5K Buy
2,729
+971
+55% +$17.7K ﹤0.01% 6543
2023
Q4
$41.5K Buy
1,758
+620
+54% +$20.2K ﹤0.01% 6654
2023
Q3
$59.1K Buy
1,138
+109
+11% +$6.56K ﹤0.01% 6191
2023
Q2
$81K Buy
1,029
+977
+1,879% +$70.1K ﹤0.01% 6170
2023
Q1
$2.15K Buy
+52
New +$2.39K ﹤0.01% 8564
2021
Q4
– Sell
-7
Closed -$1K – 10463
2021
Q3
$1K Buy
+7
New +$1.02K ﹤0.01% 9191
2021
Q2
– Sell
-81
Closed -$27K – 9570
2021
Q1
$27K Buy
+81
New +$27.7K ﹤0.01% 7095

Other funds holding IMA

UBS Group's IMA Position: Q3 2026 in Review

UBS Group increased its ImageneBio (IMA) stake by 4.1% in Q3 2026, buying an estimated $1.54K and bringing the position to 7,163 shares worth $32.8K. The position accounts for ﹤0.01% of the portfolio, ranked #8018.

UBS Group first reported a position in IMA in Q1 2021 and has held it in 17 quarters since. The position peaked at $129K in Q1 2025. 30 funds tracked by Wall St. Rank hold IMA as of Q3 2026.

  • UBS Group held 7,163 shares of ImageneBio worth $32.8K as of Q3 2026.
  • UBS Group bought 284 ImageneBio shares in Q3 2026, an estimated $1.54K.
  • ImageneBio made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8018 holding.
  • UBS Group first reported a position in ImageneBio in Q1 2021 and has held it in 17 quarters since.
  • UBS Group's ImageneBio position peaked at $129K in Q1 2025.
  • 30 funds tracked by Wall St. Rank held ImageneBio as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.